FDA discusses measures to avoid failures with new industry fees plan
This article was originally published in Scrip
The US FDA is pressing on with efforts to gather input on how its next prescription drug user fee programme should be framed and consider how performance failures associated with its current user fee programme, PDUFA IV, can be avoided.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.